Nörokütanöz Hastalıkların Dermatolojik Bulguları ve Yönetimi

Riccardi VM. Mast-cell stabilization to decrease neurofibroma growth. Preliminary experience with ketotifen. Arch Dermatol. 1987;123:1011–6.

Pivnick EK, Riccardi VM. The Neurofibromatosis. In: Freedberg IM, Eisen AZ, Wolff K, et al. Fitzpatrick’s Dermatology in General Medicine. 6 th edn. New York. McGraw-Hill, 2003: 1825–33.

Storm FK, Eilber FR, Mirra J, Morton DL. Neurofibrosarcoma. Cancer. 1980; 45:126–9

Zvulunov A, Barak Y, Metzker A. Juvenile xanthogranuloma, neurofibromatosis, and juvenile chronic myelogenous leukemia. World statistical analysis. Arch Dermatol. 1995;131(8): 904-8.

Kajimoto A, Oiso N, Fukai K, Ishii M. Bilateral segmental neurofibromatosis with gastric carcinoma. Clin Exp Dermatol. 2007;32(1):43-4.

Kaymak Y, Başsoy BÖ. Becker Nevüs ve Hamartomun Eşlik Ettiği Bir Nörofibromatoz Tip 1 Olgusu. Turkiye Klinikleri J Dermatol. 2015;25(3):108–12.

Neurofibromatosis-conference statement. National Institutes of Health consensus Development Conference. Arch Neurol. 1988;45: 575–8

DeBella K, Szudek J, Friedman JM. Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics. 2000; 105: 608-14.

Gutmann DH, Aylsworth A, Carey JC, et al. The Diagnostic evaluation and multidisciplanry management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 1997;278:51-7

Méni C, et al. Treatment of neurofibromas with a carbon dioxide laser: a retrospective cross-sectional study of 106 patients. Dermatology. 2015;230(3):263–268.

Kriechbaumer LK, Susani M, Kircher SG, Distelmaier K, Happak W. Comparative study of CO2 and Er: YAG laser ablation of multiple cutaneous neurofibromas in von Recklinghausen's disease. Lasers in Medical Science. 2014;29: 1083–1091

Verma SK, et al. Considerations for development of therapies for cutaneous neurofibroma. Neurology. 2018;91(2 suppl 1):S21–S30

Allaway RJ, Gosline SJC, La Rosa S, et al. . Cutaneous neurofibromas in the genomics era: current understanding and open questions. Br J Cancer 2018; 118: 1539-48.

Riccardi VM. Ketotifen suppression of NF1 neurofibroma growth over 30 years. Am J Med Genet A. 2015;167:1570-7.

Chamseddin BH, et al. Management of cutaneous neurofibroma: current therapy and future directions. Neurooncol Adv. 2019 Dec 16;2 (Suppl 1):i107-i116.

Jimbow K. Tuberous sclerosis and guttate leukodermas. Semin Cutan Med Surg. 1997;16:30-5

Hurwitz S, Braverman IM. White spots in tuberoussclerosis. J Pediatr. 1970;77:587-94

Schaffer JV, Gohara MA, McNiff JM, Aasi SZ, Dvoretzky I. Multiple facial angiofibromas: a cutaneous manifestation of Birt-Hogg-Dubé syndrome J Am Acad Dermatol. 2005; 53: pp. S108

Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372(9639):657-68.

Webb DW, Clarke A, Fryer A, Osborne JP. The cutaneous features of tuberous sclerosis: a population study. Br J Dermatol. 1996;135: 1-5

Northrup H, Krueger DA, International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013; 49: 243-54.

Wood BJ, Ramkaransingh JR, Fojo T, et al. Percutaneous tumor ablation with radiofrequency. Cancer. 2002;94:443-51.

Gomes AA, Gomes YV, Lima FB, Pessoa SG. Multiple facial angiofibromas treated with high-frequency equipment. An Bras Dermatol. 2011; 86: pp. S186-S189

Schepis C, Siragusa M. Cryosurgery: an easy and cheap therapy for facial angiofibromas in tuberous sclerosis. Eur J Dermatol. 2010; 20: pp. 506-507

Capurro S, Fiallo P. Timed surgery for treatment of angiofibromas in tuberous sclerosis Dermatol Surg. 2001; 27: pp. 486-488

Hori K, Soejima K, Nozaki M, Sakurai H, Takeuchi M, Yamaki T, et al. Treatment of facial angiofibroma of tuberous sclerosis using cultured epithelial autografts. Ann Plast Surg. 2006; 57: pp. 415-417

Janniger CK, Goldberg DJ. Angiofibromas in tuberous sclerosis: comparison of treatment by carbon dioxide and argon laser. J Dermatol Surg Oncol. 1990;16: pp. 317-320

Belmar P, Boixeda P, Baniandres O, Fernandez-Lorente M, Arra-zola JM. Long-term follow up of angiofibromas treated with CO2laser in 23 patients with tuberous sclerosis. Actas Dermosifiliogr.2005;96:498-503

Weinberger CH, Endrizzi B, Hook KP, Lee PK. Treatment of angiofibromas of tuberous sclerosis with 5-aminolevulinic acid blue light photodynamic therapy followed by immediate pulsed dye laser. Dermatol Surg. 2009;35:1849-51

Wang L, Gao L, Abe T, Mizoguchi M. Effects of tranilast on angiofibromas of tuberous sclerosis. Pediatr Int. 1999;41:701-3

Turkmen M, Ertam I, Unal I, Dereli T. Facial angiofibromas of tuberous sclerosis: successful treatment with podophyllin. J EurAcad Dermatol Venereol. 2009;23:713-4

Dabora SL, Franz DN, Ashwal S, et al. Multicenter phase 2 trial of sirolimus for tuberoussclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease. PLoS One. 2011; 6: e23379

Haemel AK, O’Brian AL, Teng JM. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis. Arch Dermatol. 2010;146:715-8

Wataya-Kaneda M, Tanaka M, Nakamura A, Matsumoto S, Katayama I. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity. Br J Dermatol. 2011;165:912–6

Wataya-Kaneda M, Tanaka M, Nakamura A, Matsumoto S,Katayama I. A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex. Arch Dermatol.2012;148:138-9.

Ho VCY, McLean DI. Benign epithelial tumors. In: Fitz patrick JB, Eisen AZ, Wolff K, Freedberg I, Austen KF, eds. 4th ed. New York: McGraw Hill; Q Rev Med. 1993. p.855-72.

Alonso-CL, Boixeda P, Reig I, de Daniel RC, Fleta-Asín B, P. Olasolo J. Carbon Dioxide Laser Treatment of Epidermal Nevi: Response and Long-Term Follow-Up. Actas Dermosifiliogr. 2012; 103 (10): 910-918

Park JH, Hwang ES, Kim SN, Kye YC. Er: YAG Laser Treatment of Verrucous Epidermal Nevi. J Dermatol Surg. 2004; 30(3): 378-381

MAR Osman, AN Kassab. Carbon dioxide laser versus erbium: YAG laser in treatment of epidermal verrucous nevus: a comparative randomized clinical study. J Dermatolog Treat. 2017; 28 (5): 452-457

Alkhalifah A, Fransen F, Le Duff F, Lacour JP, Wolkerstorfer A, Passeron T. Laser treatment of epidermal nevi: A multicenter retrospective study with long-term follow-up. J Am Acad Dermatol. 2020; 83(6): 1606-1615

Attia A, Elbasiouny MS. Treatment of Verrucous Epidermal Nevus Using Long Pulsed Nd: YAG Laser. Egyptian Dermatology Online Journal. 2010 6 (1): 2

Baba T, Narumi H, Hanada K, Hashimoto I. Successful Treatment of Dark‐colored Epidermal Nevus with Ruby Laser. J Clin Dermatol. 1995; 22(8): 567-570

Kim JJ, Chang MW, Shwayder T. Topical tretinoin and 5-fluorouracil in the treatment of linear verrucous epidermal nevus. J Am Acad Dermatol 2000;43:129-32.

Sandoval KR, Machado MCR, Oliveira ZNP, Nico MMS. CHILD syndrome: successful treatment of skin lesions with topical lovastatin and cholesterol lotion. An Bras Dermatol. 2019 Jul 26;94(3): 341-343.

Pascual-Castroviejo I, Pascual-Pascual SI, Velázquez-fragua R, Lapunzina P. Oculocerebrocutaneous (Delleman) syndrome: report of two cases. Neuropediatrics. 2005; 36: 50–4.

Nguyen D, Turner JT, Olsen C, et al. Cutaneous manifestations of Proteus syndrome: correlations with general clinical severity. Arch Dermatol 2004; 140: 947–53.

Busch RM, Chapin JS, Mester J, et al. Cognitive characteristics of PTEN hamartoma tumor syndromes. Genet Med. 2003 15:548–53.

Reddy KVK, Anusha A, Maloth KN, Sunitha K, Thakur M. Mucocutaneous manifestations of Cowden's syndrome. Indian Dermatol Online J. 2016; 7(6): 512–515.

Cnudde F, Boulard F, Muller P, Chevallier J, Teron-Abou B. Cowden disease: treatment with acitretine. Ann Dermatol Venereol. 1996, 123(11):739-741

Tallman B, Tan OT, Morelli JG, et al. Location of port-wine stains and the likelihood of ophthalmic and/or central nervous system complications. Pediatrics 1991; 87: 323–7.

Brightman LA, Geronemus RG, Reddy KK. Laser treatment of port-wine stains. Clin Cosmet Investig Dermatol. 2015; 8: 27–33.

Pascual-Castroviejo I, Viaño J, Moreno F, et al. Hemangiomas of the head, neck and chest with associated vascular and brain anomalies: a complex neurocutaneous syndrome. AJNR Am J Neuroradiol. 1996; 17: 461–71.

Joerger M, Koberle D, Neumann HP, Gillosen S Von Hippel–Lindau disease—a rare disease important to recognize. Onkologie. 2005; 28: 159–63.

Abdalla SA, Letarte M Hemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J Med Genet 2006; 43: 97–110.

Legierse CM, Canninga-Van Dijk MR, Bruijnzeel-Koomen CA, Kuck-Koot VC Sneddon syndrome and the diagnostic value of skin biopsiesthree young patients with intracerebral lesions and livedo racemosa. Eur J Dermatol 2008; 18: 322–8.

Eiris-Puñal J, Picon-Cotos M, Viso-Lorenzo A, Castro-Gago M. Epileptic disorder as the first neurologic manifestation of blue rubber bleb nevus syndrome. J Child Neurol. 2002; 17: 219–22.

Alomari AI, Orbach DB, Mulliken JB, Bisdorff A, Fishman SJ, Norbash A, et al. Klip pel-Trenaunay syndrome and spinal arteriovenous malformation: an erroneous associati on. Am J Neuro radiol. 2010; 31(9): 1608-12.

Maramattom BV, Cohen-Gadol AA, Wijdicks EF, Kalmas D. Segmental cutaneous hemangioma and spinal arteriovenous malformation (Cobb syndrome). Case record and historical perspective. J Neurosurg Spine. 2005; 3: 249–52.

Pilarski R, Stephens JA, Noss R, et al. Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan–Riley–Ruvalcaba syndrome clinical features. J Med Genet. 2011; 48: 505–12.

Garavelli L, Leask K, Zanacca C, et al. MRI and neurological findings in macrocephaly–cutis marmorata telangiectatica congenita syndrome: report of 10 cases and review of the literature. Genet Couns. 2005; 16: 117–28.

Chung EO, Bodensteiner JB, Noorani PA, Schochet SS. Cerebral white-matter changes suggesting leukodystrophy in ataxia telangiectasia. J Child Neurol. 1994; 9: 31–5.

Privette ED, Ram G, Treat JR, Yan AC, Heimall JR. Healing of Granulomatous Skin Changes in Ataxia‐Telangiectasia After Treatment with Intravenous Immunoglobulin and Topical Mometasone 0.1% Ointment. Pediatr Dermatol. 2014; 31(6): 703-707

Hare McCoppin HH, Goldberg DJ. Laser treatment of facial telangiectases: An update. Dermatol Surg. 2010;36(8):1221-30.

Alikhan A, Lee AD, Swing D, et al. Vaccination as a probable cause of incontinentia pigmenti reactivation. Pediatr Dermatol. 2010; 27: 62–4.

Ardelean D, Pope E. Incontinentia pigmenti in boys: a series and review of the literature. Pediatr Dermatol. 2006; 23: 523-7.

Jessup CJ, Morgan SC, Cohen LM, Viders DE. Incontinentia pigmenti: treatment of IP with topical tacrolimus. J Drugs Dermatol. 2009, 8(10):944-946

Nagase T, Takanashi M, Takada H, Ohmori K. Extensive vesiculobullous eruption following limited ruby laser treatment for incontinentia pigmenti: A case report. Australas J Dermatol. 1997; 38(3): 155-157

Kaya TI, Tursen U, İkizoğlu G. Therapeutic use of topical corticosteroids in the vesiculobullous lesions of incontinentia pigmenti. Clin Exp Dermatol. 2009; 34(8): e611-e613

Hashimoto K, Yoshikawa K. A case of incontinentia pigmenti treated with short-term systemic corticosteroid. Skin research. 1992; 34(2): 206-211

Donati P, Muscardin L, Amantea A, Paolini F. Venuti a detection of HPV‐15 in painful subungual tumors of incontinentia pigmenti: successful topical therapy with retinoic acid. Eur J Dermatol. 2009; 19: 243– 247.

Barros B, Helm K, Zaenglein A, Seiverling E. Keratoacanthoma‐Like Growths of Incontinentia Pigmenti Successfully Treated with Intralesional Methotrexate. Pediatr Dermatol. 2017; 34(4): e203-e204

Bodemer C, Diociaiuti A, Rabia SH, Robert MP, Desguerre I, Manière MC, et.al. Multidisciplinary consensus recommendations from a European network for the diagnosis and practical management of patients with incontinentia pigmenti. J Eur Acad Dermatol Venereol. 2020; 34(7): 1415-1424

Ito M. Studies on melanin XI. Incontinentia pigmenti achromians. A singular case of nevus depigmentosus systematicus bilateralis. Tohoku J Exp Med 1952; 55: 57-59.

Amal C, Litaiem N. " hypomelanosis of Ito." StatPearls [İnternet] (2020).

Sharma, P, Nicoli, E. R, Serra-Vinardell, J, Morimoto, M, Toro, C, Malicdan, MCV, & Introne, W. J. Chediak-Higashi syndrome: a review of the past, present, and future. Drug Discovery Today: Disease Models. Elsevier. 2020; 31: 31-36

Sarkozy A, Conti E, Digillio MC, et al. Clinical and molecular analysis of 30 patients with multiple lentigines LEOPARD syndrome. J Med Genet. 2004;41:68.

Ganemo A, Jagell S, Vahlquist A. Sjogren-larsson syndrome: a study of clinical symptoms and dermatological treatment in 34 Swedish patients. Acta Derm Venereol. 2009; 89:68–73.

Lambert WC, Gagna EC, and Lambert MW. "Trichothiodystrophy: Photosensitive, TTD-P, TTD, Tay Syndrome." Diseases of DNA Repair. Springer. 2010: 106-110.

Kiwilsza M, Tutak KS. Gorlin-Goltz syndrome – a medical condition requiring a multidisciplinary approach. Med Sci Monit. 2012; 18(9): 145–153.

Osiecka BJ, Nockowski P, Szepietowski JC. The use of the photodynamic method in the treatment of recurrent basal cell carcinoma on the example of Gorlin‐Goltz syndrome‐management algorithm. Dermatol Ther. 2020; 33 (6): e14499

Aydın H, Yologlu Z, Sargın H, Metin MR. Parry-Romberg syndrome Physical, clinical, and imaging features. Neurosciences . 2015; 20(4): 368–371.